ImmunityBio
IBRX
131 hedge funds and large institutions have $125M invested in ImmunityBio in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 54 increasing their positions, 33 reducing their positions, and 31 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 33
0.63% less ownership
Funds ownership: 8.95% → 8.32% (-0.63%)
5% less call options, than puts
Call options by funds: $1.99M | Put options by funds: $2.08M
12% less funds holding
Funds holding: 149 → 131 (-18)
37% less capital invested
Capital invested by funds: $200M → $125M (-$74.4M)
45% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.19M |
| 2 |
Millennium Management
New York
|
+$2.29M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.76M |
| 4 |
Renaissance Technologies
New York
|
+$1.61M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$19.6M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$2.24M |
| 3 |
Rafferty Asset Management
New York
|
-$1.99M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$861K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$764K |
IBRX Hedge Fund Activity: Q2 2022 in Review
131 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2022, worth a combined $125M — down 37% from $200M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of IBRX and 17 opened new positions — a net loss of 14 holders — while 33 trimmed existing stakes and 54 added.
The largest buyer was BlackRock, adding an estimated $3.19M. The largest seller was State Street, cutting an estimated $19.6M.
- 131 institutional investors held ImmunityBio (IBRX) as of Q2 2022, down from 149 in Q1 2022.
- Funds reported $125M of ImmunityBio stock for Q2 2022, down 37% quarter-over-quarter.
- 17 funds opened new ImmunityBio positions in Q2 2022 and 31 closed out, a net change of -14 holders.
- The largest ImmunityBio buyer in Q2 2022 was BlackRock, an estimated $3.19M added.
- The largest ImmunityBio seller in Q2 2022 was State Street, an estimated $19.6M sold.
Based on aggregated 13F filings for Q2 2022.